Genetic strategies for brain tumor therapy (Q36247099)

13 August 2017

1 reference

title

Genetic strategies for brain tumor therapy (English)

1 reference

13 August 2017

1 reference

Lawler SE

1

1 reference

PubMed ID

16138122

13 August 2017

Peruzzi PP

series ordinal

2

1 reference

PubMed ID

16138122

13 August 2017

Chiocca EA

series ordinal

3

1 reference

13 August 2017

1 March 2006

1 reference

13 August 2017

1 reference

13 August 2017

13

1 reference

13 August 2017

3

1 reference

13 August 2017

225-233

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700886

13 August 2017

0 references

cites work

Brain tumor survival: results from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Viral therapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Recombinant retrovirus vectors for treatment of malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

A novel E1A-E1B mutant adenovirus induces glioma regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Cancer gene therapy through autonomous parvovirus--mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Neural stem cell biology may be well suited for improving brain tumor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Endothelial progenitor cells' "homing" specificity to brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Use of suicide genes for cancer gene therapy: study of the different approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Cytokine gene therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Gene therapy of experimental brain tumors using neural progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Altered molecular pathways in gliomas: an overview of clinically relevant issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Anti‐erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

RNA interference against a glioma-derived allele of EGFR induces blockade at G2M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Gene therapy using an adenovirus vector for apoptosis-related genes is a highly effective therapeutic modality for killing glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Apoptosis-targeted therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Undermining tumor angiogenesis by gene therapy: an emerging field

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Molecular mechanisms of glioma invasiveness: the role of proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP-2 and PTEN gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

Virus-mediated killing of cells that lack p53 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

inferred from DOI database lookup

7 January 2021

based on heuristic

Gene therapy for malignant glioma patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of extracellular matrix components in a highly infiltrative in vivo glioma model.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700886

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700886

1 reference

13 August 2017

1 reference

PubMed ID

16138122